Literature DB >> 31342441

RNA Therapeutics: How Far Have We Gone?

Maria Francisca Coutinho1, Liliana Matos1, Juliana Inês Santos1, Sandra Alves2.   

Abstract

In recent years, the RNA molecule became one of the most promising targets for therapeutic intervention. Currently, a large number of RNA-based therapeutics are being investigated both at the basic research level and in late-stage clinical trials. Some of them are even already approved for treatment. RNA-based approaches can act at pre-mRNA level (by splicing modulation/correction using antisense oligonucleotides or U1snRNA vectors), at mRNA level (inhibiting gene expression by siRNAs and antisense oligonucleotides) or at DNA level (by editing mutated sequences through the use of CRISPR/Cas). Other RNA approaches include the delivery of in vitro transcribed (IVT) mRNA or the use of oligonucleotides aptamers. Here we review these approaches and their translation into clinics trying to give a brief overview also on the difficulties to its application as well as the research that is being done to overcome them.

Entities:  

Keywords:  Antisense oligonucleotides; Aptamers; CRISPR-Cas gene editing; Modified mRNA replacement therapy; U1snRNA vectors; siRNA-based drugs

Mesh:

Substances:

Year:  2019        PMID: 31342441     DOI: 10.1007/978-3-030-19966-1_7

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  18 in total

1.  How to Design U1 snRNA Molecules for Splicing Rescue.

Authors:  Liliana Matos; Juliana I Santos; Mª Francisca Coutinho; Sandra Alves
Journal:  Methods Mol Biol       Date:  2022

2.  Structural Fingerprinting of siRNA Therapeutics by Solution NMR Spectroscopy.

Authors:  Owen B Becette; Anh Tran; Jace W Jones; John P Marino; Robert G Brinson
Journal:  Nucleic Acid Ther       Date:  2022-03-09       Impact factor: 4.244

Review 3.  Targeting Akt-associated microRNAs for cancer therapeutics.

Authors:  Mir S Adil; Daulat Khulood; Payaningal R Somanath
Journal:  Biochem Pharmacol       Date:  2020-12-24       Impact factor: 6.100

Review 4.  RNA therapeutics for retinal diseases.

Authors:  Michael C Gemayel; Ashay D Bhatwadekar; Thomas Ciulla
Journal:  Expert Opin Biol Ther       Date:  2020-12-16       Impact factor: 5.589

Review 5.  Emerging Roles of RNA 3'-end Cleavage and Polyadenylation in Pathogenesis, Diagnosis and Therapy of Human Disorders.

Authors:  Jamie Nourse; Stefano Spada; Sven Danckwardt
Journal:  Biomolecules       Date:  2020-06-17

Review 6.  Fetal gene therapy and pharmacotherapy to treat congenital hearing loss and vestibular dysfunction.

Authors:  Michelle L Hastings; John V Brigande
Journal:  Hear Res       Date:  2020-03-05       Impact factor: 3.208

Review 7.  Investigational Treatments for Epidermolysis Bullosa.

Authors:  Ping-Chen Hou; Han-Tang Wang; Stasha Abhee; Wei-Ting Tu; John A McGrath; Chao-Kai Hsu
Journal:  Am J Clin Dermatol       Date:  2021-07-22       Impact factor: 7.403

8.  Rational design of antisense oligonucleotides modulating the activity of TLR7/8 agonists.

Authors:  Arwaf S Alharbi; Aurélie J Garcin; Kim A Lennox; Solène Pradeloux; Christophe Wong; Sarah Straub; Roxane Valentin; Geneviève Pépin; Hong-Mei Li; Marcel F Nold; Claudia A Nold-Petry; Mark A Behlke; Michael P Gantier
Journal:  Nucleic Acids Res       Date:  2020-07-27       Impact factor: 16.971

Review 9.  Lysosomal Storage Disease-Associated Neuropathy: Targeting Stable Nucleic Acid Lipid Particle (SNALP)-Formulated siRNAs to the Brain as a Therapeutic Approach.

Authors:  Maria Francisca Coutinho; Juliana Inês Santos; Liliana S Mendonça; Liliana Matos; Maria João Prata; Amália S Jurado; Maria C Pedroso de Lima; Sandra Alves
Journal:  Int J Mol Sci       Date:  2020-08-10       Impact factor: 5.923

Review 10.  Precision medicine in Parkinson's disease: emerging treatments for genetic Parkinson's disease.

Authors:  Susanne A Schneider; Roy N Alcalay
Journal:  J Neurol       Date:  2020-01-23       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.